What FDA Warning Letters Actually Say About Peptide Marketing

The cheapest compliance research nobody does

There is a public, searchable record of exactly which sentences drew federal attention in this category, who wrote them, and what the agency called the violation. It is free, it updates continuously, and almost nobody selling research peptides reads it on a schedule.

The FDA publishes warning letters through its warning letters index, and maintains a separate consumer-facing health fraud series that lists letters by year. Reading a month of it teaches an operator more about where the line sits than any summary, including this one.

This article works from that record. It is not legal advice, and it does not predict what any agency will do next. It reports what the published record already shows.

What the record actually names

The FDA's own health fraud tables list the recipient, the issuing center, the stated subject, and the date. Four entries in the 2024 table are directly relevant to this category, and they are worth reproducing exactly as the agency lists them.

• Swisschems, Center for Drug Evaluation and Research, Unapproved New Drugs/Misbranded, 10/24/2024

• Xcel Research LLC, Center for Drug Evaluation and Research, Unapproved New Drugs/Misbranded, 12/10/2024

• Prime Vitality, Inc. dba Prime Peptides, Center for Drug Evaluation and Research, Unapproved New Drugs/Misbranded, 12/10/2024

• Summit Research Peptides, Center for Drug Evaluation and Research, Unapproved New Drugs/Misbranded, 12/10/2024

Source: the FDA's 2024 warning letters, health fraud listing.

Three of those four names contain the words peptide or research. Three were issued on the same day. All four carry the identical subject line.

Read the subject line again

Unapproved New Drugs/Misbranded is not a description of a product. It is a description of a legal status the agency assigned to something the recipient believed was a research material.

That status did not arrive because the substance changed. It arrived because of what the sellers said. Under the Code of Federal Regulations (CFR), at 21 CFR 201.128, intended use refers to the objective intent of the persons legally responsible for the labeling of an article, and that intent may be shown by labeling claims, advertising matter, or oral or written statements by those persons or their representatives.

An operator reading that provision alongside the warning letter table is looking at cause and effect. The provision describes the mechanism. The table shows the mechanism running.

What the pattern tells you, and what it does not

Four entries is a small sample, and it would be dishonest to build a statistical claim on it. What the sample does support is narrower and more useful.

The research use only (RUO) label was present and did not change the outcome. Every business in that list operated in a category that uses research-use positioning as standard practice. The agency assigned the drug status anyway. That is consistent with the regulatory structure, because the phrase everyone borrows comes from 21 CFR 809.10, a labeling provision for in vitro diagnostic products, and it was never a general exemption from drug regulation.

The issuing center is CDER. The Center for Drug Evaluation and Research (CDER) handles drugs. A letter arriving from CDER rather than from a food or supplement office tells you which framework the agency applied.

The subject is not about product quality. Nothing in that subject line concerns purity, contamination or manufacturing. The violation is about status and representation. An operator with immaculate certificates of analysis and loose marketing language sits exactly where these four sat.

What the sample does not support is any prediction about enforcement volume, priority, or who is next. Anyone offering you that is guessing.

Where the same record goes further back

The health fraud series runs across years, and the useful exercise is not to read one year but to notice what stays constant.

The 2023 listing and the 2021 listing carry the same structure and the same recurring subjects. Unapproved new drugs and misbranding appear year after year across very different product categories. The categories rotate. The violation does not.

That stability is the actual finding. An operator waiting for enforcement attention to move on to some other corner of the market is waiting for something the record gives no reason to expect.

How to run this as a procedure

Reading warning letters is only useful if it changes something. The version that works is short and repeatable.

• Once a month, open the index and filter to the current year. Twenty minutes is enough. You are looking for recipients in adjacent categories, not only your own.

• Record the subject line verbatim. The agency's own characterisation is the signal. Paraphrasing it loses the framework it implies.

• For each relevant letter, ask one question about your own site. Would the same reading of my pages produce the same subject line? Not "is my product different", which is the reflex, but "is my representation different".

• Convert each answer into a specific edit or an explicit decision. A letter that changes nothing has not been read, it has been skimmed.

• Log the review with a date. A compliance posture that cannot show when it last looked is a posture nobody can audit, including you.

The specific pages most exposed

Working backwards from the framework these letters apply, the highest-exposure surfaces on a typical research peptide site are not the ones operators worry about.

The product description is usually careful, because everyone knows to be careful there. The exposure concentrates in the places that feel like copywriting rather than compliance.

Calls to action that invite a reader to begin something. Category pages named after a bodily outcome. Mission and about copy describing what the company is for. Support macros written once and reused thousands of times. Creator briefs that specify a feeling rather than a fact. Each of those is an oral or written statement by a person responsible for the labeling, which is the exact language the provision uses.

The FDA also maintains a broader unapproved drugs programme page, which is worth reading once for context on how the agency frames the category as a whole.

Checking approval status rather than assuming it

One recurring error in this space is worth isolating, because it is easy to fix and expensive to get wrong.

Statements about whether a molecule is approved should come from a lookup, not from recall. The authoritative record is Drugs@FDA, and it takes less time to check than the sentence takes to write. Approval status also changes, which means a statement that was accurate when published can become inaccurate without anyone touching the page. Recording the date of the lookup is what makes that visible later.

What the statute behind the letters says

The letters are downstream of a statute, and reading it once removes a lot of confusion about why the subject line reads the way it does.

The United States Code (USC) provision 21 USC 331 enumerates prohibited acts under the Federal Food, Drug, and Cosmetic Act, including the introduction into interstate commerce of articles that are adulterated or misbranded. Misbranding is a labeling and representation concept rather than a quality concept, which is why a product can be exactly what the certificate says it is and still be misbranded.

Put the three pieces in order and the sequence is mechanical. Representations establish intended use under 21 CFR 201.128. Intended use determines what the article legally is. If what it legally is has no approval and its labeling does not match that status, the prohibited acts provision is in scope. Nothing in that chain depends on the molecule. Every link depends on the words.

This is also why the remedy is usually editorial rather than operational. The four recipients above did not need a different supply chain. They needed different sentences, and the record suggests they found that out after the fact rather than before.

The one habit that separates the two outcomes

Across every version of this that plays out publicly, the difference between a business that gets a letter and one that does not is rarely product quality and rarely intent. It is whether anyone in the company is assigned to read what the company publishes as a regulator would read it.

That is a role, not an attitude. Somebody opens the site monthly, reads it without the founder's context, and asks a single question of each page: what does this page establish about what the product is for. A team that has nobody doing that is relying on every individual writer to hold the whole framework in their head while writing marketing copy, which is not a plan.

Frequently asked questions

Does a warning letter mean the company was breaking the law?

A warning letter states the agency's position that it observed violations. It is not an adjudication. For an operator the useful reading is not about guilt, it is about which representations attracted the analysis.

Our labeling says research use only. Does the record suggest that protects us?

The four 2024 entries above operated in a category where that labeling is standard, and the agency assigned the drug status regardless. The labeling provision that phrase comes from concerns in vitro diagnostic products.

How far back should we read?

One year is enough to calibrate. The value of going further back is seeing that the recurring subjects stay the same across very different product categories, which is an argument against waiting for attention to move elsewhere.

Is this legal advice?

No. It reports what a public federal record lists, with links to the source pages. Your specific situation belongs with qualified counsel.

Where this fits

The mechanism these letters apply is explained in what Research Use Only actually means. The separate advertising-substantiation track, which runs independently of the FDA question, is covered in the FTC track. The page-level application is in anatomy of a compliant product page.

All compounds referenced anywhere on this site are supplied strictly for laboratory research purposes only. Nothing here is for human consumption, and nothing here is intended to diagnose, treat, cure, or prevent any disease.